Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell lymphomas
HSP90 is critical for the maintenance of cellular proteostasis. In cancer cells, HSP90 also becomes a nucleating site for the stabilization of multiprotein complexes including signaling pathways and transcription complexes. Here we describe the role of this HSP90 form, referred to as oncogenic HSP90...
Main Authors: | Calvo-Vidal, M Nieves (Author), Zamponi, Nahuel (Author), Krumsiek, Jan (Author), Stockslager, Max A (Author), Revuelta, Maria V (Author), Phillip, Jude M (Author), Marullo, Rossella (Author), Tikhonova, Ekaterina (Author), Kotlov, Nikita (Author), Patel, Jayeshkumar (Author), Yang, Shao Ning (Author), Yang, Lucy (Author), Taldone, Tony (Author), Thieblemont, Catherine (Author), Leonard, John P (Author), Martin, Peter (Author), Inghirami, Giorgio (Author), Chiosis, Gabriela (Author), Manalis, Scott R (Author), Cerchietti, Leandro (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
American Association for Cancer Research (AACR),
2021-10-15T13:56:42Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90).
by: Dea Shahinas, et al.
Published: (2013-01-01) -
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway
by: Benet Pera, et al.
Published: (2018-02-01) -
Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma
by: Blasberg Ronald, et al.
Published: (2010-10-01) -
Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90.
by: Tony Taldone, et al.
Published: (2010-06-01) -
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
by: Li Zihai, et al.
Published: (2010-10-01)